- Home
- CCEC vs IMTX Comparison
CCEC vs IMTX Comparison
Compare CCEC & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEC | IMTX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | Greece | Germany |
| Employees | N/A | 423 |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CCEC | IMTX |
|---|---|---|
| Price | $23.30 | $9.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $25.50 | $19.25 |
| AVG Volume (30 Days) | 7.2K | ★ 353.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.29 | N/A |
| Revenue Next Year | $12.32 | $19.39 |
| P/E Ratio | $4.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.09 | $3.30 |
| 52 Week High | $24.83 | $12.41 |
Technical Indicators
Market Signals| Indicator | CCEC | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.88 | 49.10 |
| Support Level | $20.16 | $9.66 |
| Resistance Level | $23.76 | $10.64 |
| Average True Range (ATR) | 1.00 | 0.55 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 99.04 | 46.40 |
Price Performance
Historical ComparisonAbout CCEC Capital Clean Energy Carriers Corp.
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.